Introduction
Mazdutide and tirzepatide are both injectable medications that target gut hormones to support weight loss and blood sugar control — but the key difference lies in how they work. Tirzepatide activates GLP-1 and GIP receptors, while mazdutide activates GLP-1 and glucagon receptors. PeptideDeck
This distinction makes the mazdutide vs tirzepatide comparison one of the most scientifically significant debates in metabolic research right now. Both compounds belong to the dual agonist class, both produce clinically meaningful weight loss results, and both are generating enormous research interest globally — yet they operate through fundamentally different second receptor mechanisms that produce meaningfully different metabolic profiles.
For researchers already exploring metabolic compounds in our peptide sciences catalog this guide breaks down everything you need to know about mazdutide vs tirzepatide — mechanisms, clinical trial data, weight loss outcomes, availability, and which compound best fits your specific research objectives.
What Is Tirzepatide?
Tirzepatide is an FDA-approved medication available in the United States as Zepbound for weight loss and Mounjaro for type 2 diabetes. It is a dual GIP/GLP-1 receptor agonist approved in 2023 for chronic weight management in adults with obesity or overweight and at least one weight-related condition. PeptideDeck
Tirzepatide has strong, well-established weight loss data from large global trials. In the SURMOUNT-1 trial, participants without diabetes who received the highest dose of 15mg lost an average of 22.5% of their body weight over 72 weeks, with lower doses of 5mg and 10mg producing weight losses of around 15–20%. –
The GIP receptor mechanism that tirzepatide adds on top of GLP-1 is believed to enhance insulin secretion, reduce glucagon levels, and improve fat metabolism — making it a uniquely powerful dual-pathway metabolic research tool. For full trial data reference visit ClinicalTrials.gov — SURMOUNT trials and PubMed tirzepatide research.
What Is Mazdutide?
Mazdutide is an investigational dual GLP-1 and glucagon receptor agonist developed through an Innovent-Lilly licensing partnership. Phase 3 trials in Chinese adults with obesity or type 2 diabetes show clinically meaningful weight loss and glycemic improvement. PeptideDeck
Mazdutide’s glucagon receptor activity is a unique feature that could potentially offer advantages in fat loss and metabolic improvement that go beyond appetite suppression alone. Early data is promising, with up to 20.1% weight loss at the 9mg dose and strong improvements in liver fat and cardiometabolic markers. –
Mazdutide is not legally available for human use in the United States as of April 2026. The compound cannot be prescribed, compounded, or dispensed by a licensed US healthcare provider under current law. It is currently approved only in China following NMPA regulatory review, with international trials underway for potential global approval. See our [retatrutide dosage chart — Internal Link] page for related triple agonist research reference. PeptideDeck
Mazdutide vs Tirzepatide — Mechanism Comparison
The core of the mazdutide vs tirzepatide debate lies in their second receptor target:
| Feature | Tirzepatide | Mazdutide |
|---|---|---|
| Class | Dual GIP/GLP-1 agonist | Dual GLP-1/Glucagon agonist |
| Primary Receptor | GLP-1 | GLP-1 |
| Second Receptor | GIP | Glucagon |
| Approval Status | FDA approved (US, UK, global) | NMPA approved (China only) |
| Brand Names | Mounjaro / Zepbound | No global brand name yet |
| Administration | Once weekly injection | Once weekly injection |
| Developer | Eli Lilly | Innovent / Eli Lilly |
Understanding the mechanism helps explain why these drugs produce different metabolic effects. GLP-1 slows gastric emptying, reduces appetite, and improves insulin secretion — the shared foundation of both compounds. The second receptor is where the approaches diverge significantly. –
Tirzepatide’s GIP activation enhances insulin sensitivity and fat storage regulation. Mazdutide’s glucagon activation increases energy expenditure and drives direct fat oxidation — a thermogenic mechanism that GIP does not replicate. This is what makes the mazdutide vs tirzepatide comparison so compelling for metabolic researchers: two different dual-pathway strategies targeting the same outcome through distinctly different biological routes.
Mazdutide vs Tirzepatide — Clinical Trial Results
In clinical trials tirzepatide produced up to 20.9% weight loss over 72 weeks and mazdutide produced up to 18.55% over 60 weeks. They have never been studied head-to-head so a direct comparison is not possible. PeptideDeck
Here is what the available trial data shows for each compound:
Tirzepatide — SURMOUNT Trial Data:
Tirzepatide has a larger body of evidence from diverse global populations and longer duration trials. Its weight loss results at 72 weeks are among the strongest seen for any anti-obesity medication currently under research. –
- SURMOUNT-1: 22.5% weight loss at 15mg over 72 weeks
- SURMOUNT-2: Significant HbA1c reduction in type 2 diabetes population
- Population: Global, diverse, large-scale trials across multiple countries
- Approval: FDA, EMA, MHRA — broad international regulatory approval
Mazdutide — GLORY Trial Data:
The GLORY-1 trial is the primary evidence base for mazdutide’s obesity indication and the data supporting NMPA approval — a Phase 3 randomized controlled trial enrolling 610 Chinese adults with obesity that was published in full in the New England Journal of Medicine in 2025. PeptideDeck
- GLORY-1: Up to 18.55% weight loss over 60 weeks
- 9mg dose: Up to 20.1% weight loss with strong liver fat reduction
- Population: Chinese adults — limited data from non-Asian populations
- Approval: NMPA China only as of May 2026
For full trial data reference visit NIH PubMed — GLORY-1 trial and ClinicalTrials.gov.
Mazdutide vs Tirzepatide — Key Differences Summarized
Both are dual-agonist injections but tirzepatide targets GLP-1 and GIP while mazdutide targets GLP-1 and glucagon. Clinical trials in China show tirzepatide achieved 17.5% average weight loss at 48 weeks compared to mazdutide’s 14% — though higher doses of mazdutide are being tested which may narrow the gap. Tydes
The most practical differences for researchers comparing mazdutide vs tirzepatide are:
- Evidence base — tirzepatide has vastly more global trial data; mazdutide evidence is primarily from Chinese populations
- Regulatory status — tirzepatide is globally approved; mazdutide is China-only as of 2026
- Metabolic mechanism — tirzepatide enhances insulin sensitivity via GIP; mazdutide increases energy expenditure via glucagon
- Liver fat research — mazdutide shows particularly strong signals in hepatic fat reduction — a potential research advantage
- Population data — direct comparisons to tirzepatide in non-Asian populations have not been completed as of April 2026 PeptideDeck
Which Is More Relevant for Research in 2026?
It is too early to say definitively which compound is superior. Tirzepatide has a larger body of evidence from diverse global populations while mazdutide’s glucagon receptor activity is a unique feature that could potentially offer advantages in fat loss and metabolic improvement beyond appetite suppression. –
For researchers focused on GIP pathway research and needing globally available, extensively documented compounds — tirzepatide remains the clear choice. For researchers specifically interested in glucagon receptor mechanisms, hepatic fat metabolism, and thermogenic energy expenditure pathways — mazdutide offers a uniquely valuable and currently underexplored research profile.
Both compounds sit alongside our retatrutide dosage chart as the most advanced metabolic peptide research tools currently available — with retatrutide being the only triple agonist targeting all three receptor pathways simultaneously. Explore our complete research peptides catalog for all available metabolic research compounds.
Availability & Regulatory Status
| Region | Tirzepatide | Mazdutide |
|---|---|---|
| United States | ✅ FDA Approved | ❌ Not Available |
| United Kingdom | ✅ MHRA Approved | ❌ Not Available |
| European Union | ✅ EMA Approved | ❌ Not Available |
| China | ✅ Available | ✅ NMPA Approved |
| Research Use | ✅ Available | ✅ Research only outside China |
Disclaimer
Both mazdutide and tirzepatide discussed in this article are referenced strictly in the context of published clinical research and scientific comparison. Mazdutide is not approved for human use outside China. Tirzepatide is only legally available through licensed prescription channels in approved regions. Neither compound should be obtained or used outside of authorized clinical, research, or prescription frameworks. For regulatory guidance visit FDA Research Use Guidelines.
Frequently Asked Questions — Mazdutide vs Tirzepatide
Q1: What is the main difference between mazdutide and tirzepatide?
Both medications target two hormone receptors but different ones — tirzepatide activates GLP-1 and GIP receptors while mazdutide activates GLP-1 and glucagon receptors, creating meaningfully different metabolic research profiles despite their shared GLP-1 foundation. PeptideDeck
Q2: Which produces more weight loss — mazdutide or tirzepatide?
In clinical trials tirzepatide produced up to 20.9% weight loss over 72 weeks and mazdutide produced up to 18.55% over 60 weeks — but they have never been studied head-to-head so a definitive direct comparison is not scientifically possible. PeptideDeck
Q3: Is mazdutide approved in the United States?
Mazdutide is not legally available for human use in the United States as of April 2026 — it cannot be prescribed, compounded, or dispensed by a licensed US healthcare provider under current law. International trials are underway for potential future global approval. PeptideDeck
Q4: What is the GLORY-1 trial?
The GLORY-1 trial is the primary evidence base for mazdutide’s obesity indication — a Phase 3 randomized controlled trial enrolling 610 Chinese adults with obesity, with full results published in the New England Journal of Medicine in 2025 and supporting NMPA approval in China. PeptideDeck
Q5: What makes mazdutide unique compared to other GLP-1 compounds?
Mazdutide’s glucagon receptor activity is a unique feature that could potentially offer advantages in fat loss and metabolic improvement beyond appetite suppression — early data shows strong improvements in liver fat and cardiometabolic markers alongside meaningful weight reduction. –
Q6: How does tirzepatide’s GIP mechanism differ from mazdutide’s glucagon mechanism?
Tirzepatide’s GIP receptor activation primarily enhances insulin secretion and improves fat storage regulation, while mazdutide’s glucagon receptor activation increases energy expenditure and drives direct fat oxidation — two fundamentally different metabolic strategies built on the same GLP-1 foundation. For full mechanistic detail visit PubMed Research Library.
Q7: Where can I find research-grade metabolic peptides?
Explore our complete [research peptides catalog — Internal Link] for all available metabolic research compounds including retatrutide, CJC 1295 Ipamorelin, and NAD+ injectable formulations — all independently verified at ≥98% purity with full COA included.